TuisTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Vorige sluiting
$3,72
Dagwisseling
$3,62 - $3,76
Jaarwisseling
$3,03 - $14,80
Markkapitalisasie
3,44 m USD
Gemiddelde volume
28,06 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 666,00 k | -53,88% |
Netto inkomste | -790,00 k | 59,90% |
Netto winsgrens | — | — |
Wins per aandeel | — | — |
EBITDA | -666,00 k | 65,46% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 2,83 m | -58,12% |
Totale bates | 2,92 m | -63,85% |
Totale aanspreeklikheid | 483,00 k | -66,55% |
Totale ekwiteit | 2,44 m | — |
Uitstaande aandele | 914,23 k | — |
Prys om te bespreek | 1,39 | — |
Opbrengs op bates | -51,03% | — |
Opbrengs op kapitaal | -58,72% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -790,00 k | 59,90% |
Kontant van bedrywe | -506,00 k | 77,47% |
Kontant van beleggings | — | — |
Kontant van finansiering | -62,00 k | -115,27% |
Netto kontantverandering | -568,00 k | 57,49% |
Beskikbare kontantvloei | -193,25 k | 80,89% |
Meer oor
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Gestig
1991
Webwerf
Werknemers
4
